Published in Psychopharmacology (Berl) on October 23, 2013
Assessment of non-BDNF neurotrophins and GDNF levels after depression treatment with sertraline and transcranial direct current stimulation in a factorial, randomized, sham-controlled trial (SELECT-TDCS): an exploratory analysis. Prog Neuropsychopharmacol Biol Psychiatry (2014) 0.81
The bipolar depression electrical treatment trial (BETTER): design, rationale, and objectives of a randomized, sham-controlled trial and data from the pilot study phase. Neural Plast (2015) 0.75
Transcranial Direct Current Stimulation Use in the Treatment of Neuropsychiatric Disorders: A Brief Review. Psychiatr Ann (2016) 0.75
Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy. J Psychopharmacol (2017) 0.75
Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. J Physiol (2000) 12.01
Transcranial direct current stimulation: State of the art 2008. Brain Stimul (2008) 6.81
Transcranial DC stimulation (tDCS): a tool for double-blind sham-controlled clinical studies in brain stimulation. Clin Neurophysiol (2006) 5.21
Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry (2000) 4.03
The functional neuroanatomy of the placebo effect. Am J Psychiatry (2002) 3.26
Clinical research with transcranial direct current stimulation (tDCS): challenges and future directions. Brain Stimul (2011) 3.25
Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology (2010) 2.97
Transcranial direct current stimulation for depression: 3-week, randomised, sham-controlled trial. Br J Psychiatry (2012) 2.83
New insights into the placebo and nocebo responses. Neuron (2008) 2.64
Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology (2000) 2.36
The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology (2011) 2.15
The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis (2008) 2.13
Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet (2011) 2.10
Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol Psychiatry (2012) 2.06
Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord (2011) 1.58
Heartache and heartbreak--the link between depression and cardiovascular disease. Nat Rev Cardiol (2012) 1.55
The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial. JAMA Psychiatry (2013) 1.54
Electrode positioning and montage in transcranial direct current stimulation. J Vis Exp (2011) 1.50
Biological markers in noninvasive brain stimulation trials in major depressive disorder: a systematic review. J ECT (2014) 1.46
Anti-inflammatory properties of desipramine and fluoxetine. Respir Res (2007) 1.38
Transcranial direct current stimulation in severe, drug-resistant major depression. J Affect Disord (2009) 1.35
Indicators of immune activation in major depression. Psychiatry Res (1996) 1.30
Behavioral conditioning of immunosuppression is possible in humans. FASEB J (2002) 1.29
Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord (2005) 1.29
A critical review of human endotoxin administration as an experimental paradigm of depression. Neurosci Biobehav Rev (2009) 1.24
Transcranial direct current stimulation (tDCS) in unipolar vs. bipolar depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry (2010) 1.23
The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci (2013) 1.21
Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology (2001) 1.19
Cytokine production and serum proteins in depression. Scand J Immunol (1995) 1.18
Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry (2009) 1.16
Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. Arch Neurol (2001) 1.14
Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clin Pharmacol Ther (2009) 1.09
A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity. Brain Behav Immun (2012) 1.09
1,5-Benzodiazepine tricyclic derivatives exerting anti-inflammatory effects in mice by inhibiting interleukin-6 and prostaglandinE(2)production. Pharmacol Res (2001) 1.03
Interactions between transcranial direct current stimulation (tDCS) and pharmacological interventions in the Major Depressive Episode: findings from a naturalistic study. Eur Psychiatry (2012) 1.02
Augmentative repetitive navigated transcranial magnetic stimulation (rTMS) in drug-resistant bipolar depression. Bipolar Disord (2009) 0.97
Sertraline vs. ELectrical Current Therapy for Treating Depression Clinical Trial--SELECT TDCS: design, rationale and objectives. Contemp Clin Trials (2010) 0.91
Polarity- and valence-dependent effects of prefrontal transcranial direct current stimulation on heart rate variability and salivary cortisol. Psychoneuroendocrinology (2012) 0.90
Heart rate variability is a trait marker of major depressive disorder: evidence from the sertraline vs. electric current therapy to treat depression clinical study. Int J Neuropsychopharmacol (2013) 0.90
Non-invasive brain stimulation and the autonomic nervous system. Clin Neurophysiol (2013) 0.90
Emerging tendency towards autoimmune process in major depressive patients: a novel insight from Th17 cells. Psychiatry Res (2010) 0.89
Reversal of chronic stress-induced pain by transcranial direct current stimulation (tDCS) in an animal model. Brain Res (2012) 0.85
Immunomodulatory effect of sertraline in a rat model of rheumatoid arthritis. Neuroimmunomodulation (2012) 0.84
Plasma levels of interleukin-6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder. Hum Psychopharmacol (2013) 0.83
Rationale and early clinical data on IL-17 blockade in psoriasis. Expert Rev Clin Immunol (2013) 0.81
A review of computational models of transcranial electrical stimulation. Crit Rev Biomed Eng (2013) 0.80
Transcranial direct current stimulation (tDCS) for depression: analysis of response using a three-factor structure of the Montgomery-Åsberg depression rating scale. J Affect Disord (2013) 0.80
The long-term high-frequency repetitive transcranial magnetic stimulation does not induce mRNA expression of inflammatory mediators in the rat central nervous system. Brain Res (2002) 0.80
A systematic review of non-invasive brain stimulation therapies and cardiovascular risk: implications for the treatment of major depressive disorder. Front Psychiatry (2012) 0.78
The role of IL-2 and soluble IL-2R in depression and antidepressant response. Curr Opin Investig Drugs (2009) 0.76
Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry (2007) 6.59
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
International Society for Bipolar Disorders Task Force on Suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disord (2014) 4.10
The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry (2003) 3.00
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry (2010) 2.98
Migraine and coronary heart disease in women and men. Headache (2002) 2.44
Brazilian Longitudinal Study of Adult Health (ELSA-Brasil): objectives and design. Am J Epidemiol (2012) 2.34
Ketamine for depression: where do we go from here? Biol Psychiatry (2012) 2.21
Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry (2011) 2.20
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology (2012) 2.17
Long-term, low-dose lithium treatment does not impair renal function in the elderly: a 2-year randomized, placebo-controlled trial followed by single-blind extension. J Clin Psychiatry (2014) 2.13
Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry (2008) 2.05
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry (2002) 2.01
A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Am Heart J (2007) 2.01
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry (2005) 1.98
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry (2013) 1.97
Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry (2007) 1.95
The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry (2010) 1.94
Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther (2009) 1.90
Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder. Biol Psychiatry (2012) 1.85
World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res (2008) 1.84
Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry (2002) 1.84
Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry (2003) 1.71
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry (2008) 1.71
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry (2012) 1.69
Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology (2010) 1.65
The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology (2006) 1.64
The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord (2009) 1.62
Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry (2008) 1.57
Cortical abnormalities in bipolar disorder investigated with MRI and voxel-based morphometry. Neuroimage (2005) 1.57
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry (2012) 1.55
The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial. JAMA Psychiatry (2013) 1.54
A descriptive epidemiology of leisure-time physical activity in Brazil, 1996-1997. Rev Panam Salud Publica (2003) 1.52
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. Lancet HIV (2016) 1.51
Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry (2009) 1.51
The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep (2007) 1.50
Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorder. Am J Psychiatry (2005) 1.48
Early stroke case-fatality rates in three hospital registries in the Northeast and Southeast of Brazil. Arq Neuropsiquiatr (2012) 1.44
Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry (2010) 1.42
Dynamic regulation of mitochondrial function by glucocorticoids. Proc Natl Acad Sci U S A (2009) 1.38
Body mass index and mortality among US male physicians. Ann Epidemiol (2004) 1.35
Habenula volume in bipolar disorder and major depressive disorder: a high-resolution magnetic resonance imaging study. Biol Psychiatry (2010) 1.32
Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors. Eur J Pharmacol (2012) 1.32
Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression. Biol Psychiatry (2013) 1.31
A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol (2009) 1.28
Differing amygdala responses to facial expressions in children and adults with bipolar disorder. Am J Psychiatry (2012) 1.27
Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology (2010) 1.25
Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry (2003) 1.25
Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav (2011) 1.24
Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur Arch Psychiatry Clin Neurosci (2009) 1.23
Suicide rates and trends in São Paulo, Brazil, according to gender, age and demographic aspects: a joinpoint regression analysis. Rev Bras Psiquiatr (2012) 1.22
A developmental study of the neural circuitry mediating motor inhibition in bipolar disorder. Am J Psychiatry (2012) 1.21
Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol (2014) 1.21
Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry (2013) 1.21
A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol (2012) 1.20
The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J Neurosci (2008) 1.19
Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx (2006) 1.19
Multifocal slow potential generation revealed by high-resolution EEG and current density reconstruction. Int J Psychophysiol (2002) 1.17
Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study. Biol Psychiatry (2005) 1.17
Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs (2012) 1.17
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry (2005) 1.16
The generators of slow potentials obtained during verbal, pictorial and spatial tasks. Int J Psychophysiol (2003) 1.16
Prefrontal cortical abnormalities in currently depressed versus currently remitted patients with major depressive disorder. Neuroimage (2010) 1.16
Automated subcortical segmentation using FIRST: test-retest reliability, interscanner reliability, and comparison to manual segmentation. Hum Brain Mapp (2012) 1.14
McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry (2008) 1.13
The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist (2009) 1.13
Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry (2004) 1.13
Regional cerebral glucose metabolic abnormalities in bipolar II depression. Biol Psychiatry (2006) 1.13
Acute stress symptoms do not worsen in posttraumatic stress disorder and abuse with a single subanesthetic dose of ketamine. Biol Psychiatry (2012) 1.12
Low plasma brain-derived neurotrophic factor and childhood physical neglect are associated with verbal memory impairment in major depression--a preliminary report. Biol Psychiatry (2008) 1.11
McLean-Harvard International First-Episode Project: two-year stability of ICD-10 diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry (2010) 1.11
A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. Proc Natl Acad Sci U S A (2010) 1.11
Taenia solium DNA is present in the cerebrospinal fluid of neurocysticercosis patients and can be used for diagnosis. Eur Arch Psychiatry Clin Neurosci (2006) 1.11
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol (2012) 1.11
Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J Neural Transm (Vienna) (2008) 1.10
Potential role of poly(adenosine 5'-diphosphate-ribose) polymerase activation in the pathogenesis of myocardial contractile dysfunction associated with human septic shock. Crit Care Med (2006) 1.10
Does lithium prevent Alzheimer's disease? Drugs Aging (2012) 1.10
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry (2006) 1.10
Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry (2012) 1.09
Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry (2011) 1.09
Prevalence of thyroid disorders among older people: results from the São Paulo Ageing & Health Study. Cad Saude Publica (2011) 1.09
Reduced cortical folding in schizophrenia: an MRI morphometric study. Am J Psychiatry (2003) 1.08
Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J Psychiatr Res (2008) 1.08
Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr Pharm Des (2009) 1.08
Letter to the editor in response to 2012 article by Frances and Jones. Bipolar Disord (2014) 1.07